Effect of comorbid migraine on propranolol efficacy for painful TMD in a randomized controlled trial

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Tchivileva, Inna E
  • Ohrbach, Richard
    • Other Affiliation: Department of Oral Diagnostic Sciences, School of Dental Medicine, University at Buffalo, State University of New York, Buffalo, NY, USA
  • Fillingim, Roger B
    • Other Affiliation: Department of Community Dentistry and Behavioral Science, College of Dentistry, University of Florida, Gainesville, FL, USA
  • Lim, Pei Feng
    • Affiliation: School of Dentistry, Center for Pain Research and Innovation
  • Giosia, Massimiliano Di
    • Affiliation: School of Dentistry, Center for Pain Research and Innovation
  • Ribeiro-Dasilva, Margarete
    • Other Affiliation: Department of Restorative Dental Science, Prosthodontics Division, College of Dentistry, University of Florida, Gainesville, FL, USA
  • Campbell, John H
    • Other Affiliation: Department of Oral and Maxillofacial Surgery, School of Dental Medicine, University at Buffalo, State University of New York, Buffalo, NY, USA
  • Hadgraft, Holly
    • Other Affiliation: Rho Inc, Durham, NC, USA
  • Willis, Janet
    • Other Affiliation: Rho Inc, Durham, NC, USA
  • Arbes, Samuel J
    • Other Affiliation: Rho Inc, Durham, NC, USA
  • Slade, Gary D
    • Affiliation: School of Dentistry, Center for Pain Research and Innovation
Abstract
  • Introduction The migraine-preventive drug propranolol is efficacious in reducing pain from temporomandibular disorder, suggesting potential modifying or mediating effects of comorbid migraine. Methods In this randomized controlled trial, myofascial temporomandibular disorder patients were treated with propranolol or placebo for 9 weeks. The primary endpoint was change in a facial pain index derived from daily symptom diaries. Linear and logistic regression models tested for a migraine × treatment-group interaction in reducing facial pain index. Counterfactual models explored changes in headache impact and heart rate as mediators of propranolol's efficacy. Results Propranolol's efficacy in reducing facial pain index was greater among the 104 migraineurs than the 95 non-migraineurs: For example, for the binary ≥ 30% reduction in facial pain index, odds ratios were 3.3 (95% confidence limits: 1.4, 8.1) versus 1.3 (0.5, 3.2), respectively, although the interaction was statistically non-significant (p = 0.139). Cumulative response curves confirmed greater efficacy for migraineurs than non-migraineurs (differences in area under the curve 26% and 6%, respectively; p = 0.081). While 9% of the treatment effect was mediated by reduced headache impact, 46% was mediated by reduced heart rate. Conclusions Propranolol was more efficacious in reducing temporomandibular disorder pain among migraineurs than non-migraineurs, with more of the effect mediated by reduced heart rate than by reduced headache impact. Study identification and registration SOPPRANO; NCT02437383; https://clinicaltrials.gov/ct2/show/NCT02437383
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • International Headache Society
License
  • Attribution-NonCommercial 4.0 International
Journal title
  • Cephalalgia
Journal volume
  • 41
Journal issue
  • 7
Page start
  • 839
Page end
  • 850
Funder
  • National Institute of Dental and Craniofacial Research
ISSN
  • 1468-2982
  • 0333-1024
Copyright date
  • 2021
Publisher
  • SAGE Publications

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 10.1177_0333102421989268.pdf 2022-02-02 Public Download